Maravai LifeSciences Holdings logo

Maravai LifeSciences HoldingsNASDAQ: MRVI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

20 November 2020

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.06 B
-82%vs. 3y high
74%vs. sector
-vs. 3y high
-vs. sector
-87%vs. 3y high
63%vs. sector
-58%vs. 3y high
53%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:20:00 GMT
$7.46+$0.11(+1.50%)

Dividend

No data over the past 3 years
$73.40 M$67.55 M
$73.40 M-$7.58 M

Analysts recommendations

Institutional Ownership

MRVI Latest News

Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024
globenewswire.com15 October 2024 Sentiment: POSITIVE

SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences Announces August and September 2024 Investor Conference Schedule
globenewswire.com12 August 2024 Sentiment: POSITIVE

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September.

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024
globenewswire.com10 July 2024 Sentiment: POSITIVE

SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai (MRVI) Advances in RNA Research With New Collaboration
zacks.com17 May 2024 Sentiment: POSITIVE

According to management at Per Maravai LifeSciences (MRVI), this advancement by TriLink is poised to enhance nucleic acid-based therapies.

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2023 Earnings Call Transcript
Seeking Alpha08 November 2023 Sentiment: NEUTRAL

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Deb Hart - Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Executive Vice President and Chief Commercial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tom Peterson - Baird Matt Larew - William Blair Michael Ryskin - Bank of America Conor McNamara - RBC Capital Markets Dan Arias - Stifel Justin Bowers - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by. My name is Tammy and I will be your conference operator today.

Maravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023
GlobeNewsWire17 October 2023 Sentiment: NEUTRAL

SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2023 financial and operating results after the market closes on Tuesday, November 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2023 Earnings Call Transcript
Seeking Alpha08 August 2023 Sentiment: NEUTRAL

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2023 Earnings Call Transcript August 7, 2023 5:00 PM ET Company Participants Debra Hart - Head of IR Carl Hull - Executive Chairman of the Board Trey Martin - CEO Kevin Herde - CFO Becky Buzzeo - CCO Drew Burch - EVP, and GM Nucleic Acid Production Conference Call Participants Matt Sykes - Goldman Sachs Conor McNamara - RBC Capital Markets Dan Leonard - Credit Suisse Catherine Schulte - Baird Justin Bowers - Deutsche Bank Tejas Savant - Morgan Stanley Madeline Mollman - William Blair John Sourbeer - UBS Operator Thank you for standing by. I would like to welcome everyone to the Quarter Two 2023 Maravai LifeSciences' Earnings Conference Call.

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2023 Earnings Call Transcript
Seeking Alpha08 May 2023 Sentiment: POSITIVE

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Chairman of the Board and Interim CEO Kevin Herde - Chief Financial Officer Becky Buzzeo - Chief Commercial Officer Trey Martin - President Biologics Safety Testing Drew Burch - EVP, Nucleic Acid Production Conference Call Participants Conor McNamara - RBC Capital Markets Catherine Schulte - Robert W. Baird Matthew Sykes - Goldman Sachs Daniel Leonard - Credit Suisse Daniel Arias - Stifel John Sourbeer - UBS Tejas Savant - Morgan Stanley Operator Good afternoon.

Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates
Zacks Investment Research08 May 2023 Sentiment: NEGATIVE

Maravai LifeSciences Holdings, Inc. (MRVI) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.54 per share a year ago.

What type of business is Maravai LifeSciences Holdings?

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

What sector is Maravai LifeSciences Holdings in?

Maravai LifeSciences Holdings is in the Healthcare sector

What industry is Maravai LifeSciences Holdings in?

Maravai LifeSciences Holdings is in the Biotechnology industry

What country is Maravai LifeSciences Holdings from?

Maravai LifeSciences Holdings is headquartered in United States

When did Maravai LifeSciences Holdings go public?

Maravai LifeSciences Holdings initial public offering (IPO) was on 20 November 2020

What is Maravai LifeSciences Holdings website?

https://www.maravai.com

Is Maravai LifeSciences Holdings in the S&P 500?

No, Maravai LifeSciences Holdings is not included in the S&P 500 index

Is Maravai LifeSciences Holdings in the NASDAQ 100?

No, Maravai LifeSciences Holdings is not included in the NASDAQ 100 index

Is Maravai LifeSciences Holdings in the Dow Jones?

No, Maravai LifeSciences Holdings is not included in the Dow Jones index

When was Maravai LifeSciences Holdings the previous earnings report?

No data

When does Maravai LifeSciences Holdings earnings report?

The next expected earnings date for Maravai LifeSciences Holdings is 07 November 2024